Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Material and Immunohistochemistry (IHC)
2.2. Statistical Analysis
3. Results
3.1. Description of the Patient’s Cohort
3.2. Change in STAT 3, 5, and 6 Expressions in PCa Compared to BPH
3.3. Influence of Systemic Therapy on STAT3, 5, and 6 Protein Levels in PCa
3.4. Influence of Systemic Therapy on STAT3, 5, and 6 Protein Levels in PCa
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Mottet, N.; van den Bergh, R.C.N.; Briers, E.; van den Broeck, T.; Cumberbatch, M.G.; De Santis, M.; Fanti, S.; Fossati, N.; Gandaglia, G.; Gillessen, S.; et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2021, 79, 243–262. [Google Scholar] [CrossRef] [PubMed]
- Siegel, D.A.; O’Neil, M.E.; Richards, T.B.; Dowling, N.F.; Weir, H.K. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity—United States, 2001–2017. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1473–1480. [Google Scholar] [CrossRef]
- Cornford, P.; van den Bergh, R.C.N.; Briers, E.; van den Broeck, T.; Cumberbatch, M.G.; De Santis, M.; Fanti, S.; Fossati, N.; Gandaglia, G.; Gillessen, S.; et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur. Urol. 2021, 79, 263–282. [Google Scholar] [CrossRef] [PubMed]
- Ebersbach, C.; Beier, A.-M.K.; Thomas, C.; Erb, H.H.H. Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer. Cancers 2021, 13, 4854. [Google Scholar] [CrossRef] [PubMed]
- Mora, L.B.; Buettner, R.; Seigne, J.; Diaz, J.; Ahmad, N.; Garcia, R.; Bowman, T.; Falcone, R.; Fairclough, R.; Cantor, A.; et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62, 6659–6666. [Google Scholar]
- Don-Doncow, N.; Marginean, F.; Coleman, I.; Nelson, P.S.; Ehrnström, R.; Krzyzanowska, A.; Morrissey, C.; Hellsten, R.; Bjartell, A. Expression of STAT3 in Prostate Cancer Metastases. Eur. Urol. 2016, 71, 313–316. [Google Scholar] [CrossRef] [Green Version]
- Spiotto, M.T.; Chung, T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000, 42, 186–195. [Google Scholar] [CrossRef]
- Oelrich, F.; Junker, H.; Stope, M.B.; Erb, H.H.; Walther, R.; Venz, S.; Zimmermann, U. Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery. Anticancer Res. 2021, 41, 3717–3729. [Google Scholar] [CrossRef] [PubMed]
- Handle, F.; Puhr, M.; Schaefer, G.; Lorito, N.; Hoefer, J.; Gruber, M.; Guggenberger, F.; Santer, F.R.; Marques, R.B.; Van Weerden, W.M.; et al. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. Mol. Cancer Ther. 2018, 17, 2722–2731. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Zhu, Y.; Lou, W.; Cui, Y.; Evans, C.P.; Gao, A.C. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2013, 74, 201–209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thomas, C.; Zoubeidi, A.; Kuruma, H.; Fazli, L.; Lamoureux, F.; Beraldi, E.; Monia, B.P.; MacLeod, A.R.; Thüroff, J.W.; Gleave, M.E. Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo. Mol. Cancer Ther. 2011, 10, 347–359. [Google Scholar] [CrossRef] [Green Version]
- Mirtti, T.; Leiby, B.E.; Abdulghani, J.; Aaltonen, E.; Pavela, M.; Mamtani, A.; Alanen, K.; Egevad, L.; Granfors, T.; Josefsson, A.; et al. Nuclear Stat5a/b predicts early recurrence and prostate cancer–specific death in patients treated by radical prostatectomy. Hum. Pathol. 2012, 44, 310–319. [Google Scholar] [CrossRef] [Green Version]
- Siciliano, T.; Simons, I.H.; Beier, A.-M.K.; Ebersbach, C.; Aksoy, C.; Seed, R.I.; Stope, M.B.; Thomas, C.; Erb, H.H.H. A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response. Life 2021, 11, 874. [Google Scholar] [CrossRef] [PubMed]
- Erb, H.H.H.; Oster, M.A.; Gelbrich, N.; Cammann, C.; Thomas, C.; Mustea, A.; Stope, M.B. Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System. Anticancer Res. 2021, 41, 3271–3279. [Google Scholar] [CrossRef]
- Erb, H.H.H.; Bodenbender, J.; Handle, F.; Diehl, T.; Donix, L.; Tsaur, I.; Gleave, M.; Haferkamp, A.; Huber, J.; Fuessel, S.; et al. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE 2020, 15, e0237248. [Google Scholar] [CrossRef]
- Udhane, V.; Maranto, C.; Hoang, D.T.; Gu, L.; Erickson, A.; Devi, S.; Talati, P.G.; Banerjee, A.; Iczkowski, K.A.; Jacobsohn, K.; et al. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Mol. Cancer Ther. 2019, 19, 231–246. [Google Scholar] [CrossRef] [Green Version]
- Puhr, M.; Hoefer, J.; Neuwirt, H.; Eder, I.E.; Kern, J.; Schäfer, G.; Geley, S.; Heidegger, I.; Klocker, H.; Culig, Z. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget 2014, 5, 12043–12056. [Google Scholar] [CrossRef] [Green Version]
- Nappo, G.; Handle, F.; Santer, F.R.; McNeill, R.V.; Seed, R.I.; Collins, A.T.; Morrone, G.; Culig, Z.; Maitland, N.J.; Erb, H.H.H. The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis 2017, 6, e342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Das, S.; Roth, C.P.; Wasson, L.M.; Vishwanatha, J.K. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 2007, 67, 1550–1564. [Google Scholar] [CrossRef]
- Remmele, W.; Stegner, H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8, 138–140. [Google Scholar]
- Patterson, S.G.; Wei, S.; Chen, X.; Sallman, D.A.; Gilvary, D.L.; Zhong, B.; Pow-Sang, J.; Yeatman, T.; Djeu, J.Y. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006, 25, 6113–6122. [Google Scholar] [CrossRef] [Green Version]
- Lim, C.P.; Cao, X. Structure, function, and regulation of STAT proteins. Mol. BioSyst. 2006, 2, 536–550. [Google Scholar] [CrossRef]
- Culig, Z. Cytokine disbalance in common human cancers. Biochim. Biophys. Acta 2011, 1813, 308–314. [Google Scholar] [CrossRef] [Green Version]
- Culig, Z.; Puhr, M. Interleukin-6: A multifunctional targetable cytokine in human prostate cancer. Mol. Cell. Endocrinol. 2012, 360, 52–58. [Google Scholar] [CrossRef]
- Culig, Z. Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am. J. Clin. Exp. Urol. 2014, 2, 231–238. [Google Scholar]
- Culig, Z.; Bartsch, G.; Hobisch, A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 2002, 197, 231–238. [Google Scholar] [CrossRef]
- Liu, X.; He, Z.; Li, C.-H.; Huang, G.; Ding, C.; Liu, H. Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer. Pathol. Oncol. Res. 2011, 18, 17–23. [Google Scholar] [CrossRef]
- Horinaga, M.; Okita, H.; Nakashima, J.; Kanao, K.; Sakamoto, M.; Murai, M. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 2005, 66, 671–675. [Google Scholar] [CrossRef]
- Mohanty, S.K.; Yagiz, K.; Pradhan, D.; Luthringer, D.J.; Amin, M.B.; Alkan, S.; Cinar, B. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget 2017, 8, 85997–86010. [Google Scholar] [CrossRef] [Green Version]
- Pencik, J.; Schlederer, M.; Gruber, W.; Unger, C.; Walker, S.M.; Chalaris, A.; Marié, I.J.; Hassler, M.R.; Javaheri, T.; Aksoy, O.; et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat. Commun. 2015, 6, 7736. [Google Scholar] [CrossRef] [Green Version]
- Meissl, K.; Macho-Maschler, S.; Müller, M.; Strobl, B. The good and the bad faces of STAT1 in solid tumours. Cytokine 2015, 89, 12–20. [Google Scholar] [CrossRef] [Green Version]
- Iglesias-Gato, D.; Chuan, Y.-C.; Wikström, P.; Augsten, S.; Jiang, N.; Niu, Y.; Seipel, A.; Danneman, D.; Vermeij, M.; Fernandez-Perez, L.; et al. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 2013, 35, 24–33. [Google Scholar] [CrossRef] [Green Version]
- Perry, J.K.; Emerald, B.S.; Mertani, H.C.; Lobie, P.E. The oncogenic potential of growth hormone. Growth Horm. IGF Res. 2006, 16, 277–289. [Google Scholar] [CrossRef]
- Roberts, C.T., Jr. IGF-1 and prostate cancer. Novartis Found Symp. 2004, 262, 193–199; discussion 199–204, 265–198. [Google Scholar]
- Barash, I. Stat5 in breast cancer: Potential oncogenic activity coincides with positive prognosis for the disease. Carcinogenesis 2012, 33, 2320–2325. [Google Scholar] [CrossRef] [Green Version]
- Boutillon, F.; Pigat, N.; Sala, L.S.; Reyes-Gomez, E.; Moriggl, R.; Guidotti, J.-E.; Goffin, V. STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. Cancers 2019, 11, 929. [Google Scholar] [CrossRef] [Green Version]
- Ostrand-Rosenberg, S.; Clements, V.K.; Terabe, M.; Park, J.M.; Berzofsky, J.A.; Dissanayake, S.K. Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent. J. Immunol. 2002, 169, 5796–5804. [Google Scholar] [CrossRef] [Green Version]
- Wang, N.; Tao, L.; Zhong, H.; Zhao, S.; Yu, Y.; Yu, B.; Chen, X.; Gao, J.; Wang, R. miR-135b inhibits tumour metastasis in prostate cancer by targeting STAT6. Oncol. Lett. 2015, 11, 543–550. [Google Scholar] [CrossRef]
- Wise, G.J.; Marella, V.K.; Talluri, G.; Shirazian, D. Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 2000, 164, 722–725. [Google Scholar] [CrossRef]
- Sheng, J.; Yang, Y.; Cui, Y.; He, S.; Wang, L.; Liu, L.; He, Q.; Lv, T.; Han, W.; Yu, W.; et al. M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death Dis. 2018, 9, 755. [Google Scholar] [CrossRef] [Green Version]
- Tam, L.; McGlynn, L.M.; Traynor, P.; Mukherjee, R.; Bartlett, J.M.S.; Edwards, J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br. J. Cancer 2007, 97, 378–383. [Google Scholar] [CrossRef]
- Oberhuber, M.; Pecoraro, M.; Rusz, M.; Oberhuber, G.; Wieselberg, M.; Haslinger, P.; Gurnhofer, E.; Schlederer, M.; Limberger, T.; Lagger, S.; et al. STAT 3 -dependent analysis reveals PDK 4 as independent predictor of recurrence in prostate cancer. Mol. Syst. Biol. 2020, 16, e9247. [Google Scholar] [CrossRef]
- Haddad, B.R.; Erickson, A.; Udhane, V.; LaViolette, P.S.; Rone, J.D.; Kallajoki, M.A.; See, W.A.; Rannikko, A.; Mirtti, T.; Nevalainen, M.T. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1642–1651. [Google Scholar] [CrossRef] [Green Version]
- Wingelhofer, B.; Neubauer, H.A.; Valent, P.; Han, X.; Constantinescu, S.N.; Gunning, P.T.; Müller, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 2018, 32, 1713–1726. [Google Scholar] [CrossRef] [Green Version]
- De Miguel, F.; Lee, S.O.; Onate, S.A.; Gao, A.C. Stat3 enhances transactivation of steroid hormone receptors. Nucl. Recept. 2003, 1, 3. [Google Scholar] [CrossRef] [Green Version]
- Malinowska, K.; Neuwirt, H.; Cavarretta, I.; Bektic, J.; Steiner, H.; Dietrich, H.; Moser, P.L.; Fuchs, D.; Hobisch, A.; Culig, Z. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Relat. Cancer 2009, 16, 155–169. [Google Scholar] [CrossRef]
- Liu, Q.; Tong, D.; Liu, G.; Xu, J.; Do, K.; Geary, K.; Zhang, D.; Zhang, J.; Zhang, Y.; Li, Y.; et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT. Cell Death Dis. 2017, 8, e3007. [Google Scholar] [CrossRef]
- Zemskova, M.; Sahakian, E.; Bashkirova, S.; Lilly, M. The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells. J. Biol. Chem. 2008, 283, 20635–20644. [Google Scholar] [CrossRef] [Green Version]
- Tan, S.-H.; Dagvadorj, A.; Shen, F.; Gu, L.; Liao, Z.; Abdulghani, J.; Zhang, Y.; Gelmann, E.P.; Zellweger, T.; Culig, Z.; et al. Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. Cancer Res. 2008, 68, 236–248. [Google Scholar] [CrossRef] [Green Version]
- Haddad, B.R.; Gu, L.; Mirtti, T.; Dagvadorj, A.; Vogiatzi, P.; Hoang, D.T.; Bajaj, R.; Leiby, B.; Ellsworth, E.; Blackmon, S.; et al. STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression. Am. J. Pathol. 2013, 182, 2264–2275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Udhane, V.; Maranto, C.; Hoang, D.; Erickson, A.; Devi, S.; Jacobsohn, K.; Iczkowski, K.; See, W.; Kilari, D.; Mirtti, T.; et al. The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment. J. Clin. Oncol. 2019, 37, 221. [Google Scholar] [CrossRef]
- Handle, F.; Prekovic, S.; Helsen, C.; Van den Broeck, T.; Smeets, E.; Moris, L.; Eerlings, R.; El Kharraz, S.; Urbanucci, A.; Mills, I.G.; et al. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Sci. Rep. 2019, 9, 13786. [Google Scholar] [CrossRef] [Green Version]
- Bishop, J.L.; Sio, A.; Angeles, A.; Roberts, M.; Azad, A.A.; Chi, K.N.; Zoubeidi, A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 2014, 6, 234–242. [Google Scholar] [CrossRef] [Green Version]
- Muir, A.; Danai, L.V.; Heiden, M.G.V. Microenvironmental regulation of cancer cell metabolism: Implications for experimental design and translational studies. Dis. Model. Mech. 2018, 11. [Google Scholar] [CrossRef] [Green Version]
- Maitland, N.J. Getting closer to prostate cancer in patients—What scientists should want from clinicians. J. Cancer Metastasis Treat. 2017, 3, 262. [Google Scholar] [CrossRef]
- Masters, J.R. HeLa cells 50 years on: The good, the bad and the ugly. Nat. Cancer 2002, 2, 315–319. [Google Scholar] [CrossRef]
Name | Company | Lot | Dilution |
---|---|---|---|
STAT3 (124H6) Mouse mAb #9139 | Cell Signaling Technology, Danvers, MA, USA | 16 | 1:300 |
Anti-STAT5a + STAT5b antibody [EPR16671-40] | Abcam, Cambridge, United Kingdom | GR3247129-1 | 1:4000 |
STAT6 (EP325) | Bio SB, Inc., Santa Barbara, CA, USA | 3425QLD05 | 1:25 |
All | HSPC | mCRPC | |||
---|---|---|---|---|---|
ADT Only | ADT + NHT | ADT + CTx | |||
Patient Number | 97 | 26 | 25 | 33 | 13 |
Median age at primary diagnosis, years | 73 | 72 | 74 | 71 | 66 |
Median PSA at primary diagnosis, ng/mL (Interquartile range IQR) | 18 (6.9; 79.0) | 6.3 (2.7; 10.2) | 15.6 (7.2; 87.6) | 49.0 (11.2;128.0) | 60.4 (28.7; 92.7) |
Neuroendocrine differentiation at primary diagnosis, % | 1.0 | 0.0 | 0.0 | 3.0 | 0.0 |
Presence of bone metastases at primary diagnosis, % | 25.0 | 3.8 | 20.0 | 30 | 62 |
Presence of lymph node metastases at primary diagnosis, % | 14 | 12 | 8.0 | 18 | 15 |
Presence of organ metastases at primary diagnosis, % | 1.00 | 0.00 | 0.0 | 3.0 | 0.0 |
Median overall survival since the start of primary therapy, months | 59 | 47 | 81 | 67 | 86 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ebersbach, C.; Beier, A.-M.K.; Hönscheid, P.; Sperling, C.; Jöhrens, K.; Baretton, G.B.; Thomas, C.; Sommer, U.; Borkowetz, A.; Erb, H.H.H. Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue. Life 2022, 12, 240. https://doi.org/10.3390/life12020240
Ebersbach C, Beier A-MK, Hönscheid P, Sperling C, Jöhrens K, Baretton GB, Thomas C, Sommer U, Borkowetz A, Erb HHH. Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue. Life. 2022; 12(2):240. https://doi.org/10.3390/life12020240
Chicago/Turabian StyleEbersbach, Celina, Alicia-Marie K. Beier, Pia Hönscheid, Christian Sperling, Korinna Jöhrens, Gustavo B. Baretton, Christian Thomas, Ulrich Sommer, Angelika Borkowetz, and Holger H. H. Erb. 2022. "Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue" Life 12, no. 2: 240. https://doi.org/10.3390/life12020240